OncoMed Pharmaceuticals (OMED) PT Raised to $16 at Jefferies

August 10, 2016 8:31 AM EDT
Get Alerts OMED Hot Sheet
Price: $7.63 -1.42%

Rating Summary:
    8 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 32 | New: 34
Trade OMED Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Jefferies analyst Brian Abrahams reiterated a Buy rating and boosted his price target on OncoMed Pharmaceuticals (NASDAQ: OMED) to $16.00 (from $15.00) following Q2 update.

Abrahams commented, "OMED will have multiple data updates in 2H16/1H17 as well as potential opt-in catalysts from collaborators. We continue to view their broad pipeline, in-depth understanding of the science, and high-profile collaboration options as an ideal mixture in small cap biotech and undervalued in today's market; expect appreciation as earlier programs start to mature and later-stage programs approach more definitive datapoints. Adjust tgt to $16 on model updates."

For an analyst ratings summary and ratings history on OncoMed Pharmaceuticals click here. For more ratings news on OncoMed Pharmaceuticals click here.

Shares of OncoMed Pharmaceuticals closed at $12.00 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment